Intend Research, LLC
Norman, Oklahoma 73069
0 studies enrolling now · 15 studies all time
What they study most
Adolescent Obesity, Adolescent Overweight, Diabetes, Obesity, Obesity in Adolescence, Overweight, Overweight and Obesity, T2D, Type 1 Diabetes Mellitus, Type 2 Diabetes, Type 2 Diabetes Mellitus
Studies at this site
- A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1) — Completed
- A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin — Completed
- A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time — Completed
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss — Completed
- A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program — Completed
- A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin — Completed
- A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus — Completed
- A Study of LY3437943 in Participants Who Have Obesity or Are Overweight — Completed
- A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities — Completed
- A Study of LY3437943 in Participants With Type 2 Diabetes — Completed
- A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range) — Completed
- A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus — Completed
- A Study of LY3209590 in Participants With Type 1 Diabetes — Completed
- A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity — Completed
- A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes — Completed